Levicept Ltd revealed Phase II clinical trial data for LEVI-04, a novel osteoarthritis treatment, at the EULAR 2026 conference. The data suggest LEVI-04 not only relieves pain but may also modify the disease by reducing bone marrow lesions linked to osteoarthritis severity. LEVI-04 showed improvements in pain and function comparable or superior to NSAIDs, with a differentiated safety profile from other treatments. Further presentations will detail its unique mechanism and clinical benefits, supporting its potential as a first-in-class therapy for osteoarthritis.
Czechoslovak Group (CSG) has secured contracts worth tens of millions of euros to supply mechanical and electronic fuzes for large-calibre ammunition to two NATO member countries in Europe. The contracts highlight growing European demand for critical...
The global protein supplements market is projected to grow from $30.3 billion in 2026 to $43.98 billion by 2031, at a CAGR of 7.74%. Growth is fueled by rising fitness participation, expanding consumer base beyond athletes, demand for convenient nutr...
The global photomask market, essential for semiconductor chip production, is projected to grow from $5.37 billion in 2025 to $8.19 billion by 2035 at a CAGR of 4.31%. Growth is fueled by rising semiconductor complexity, AI, 5G, IoT applications, and ...
The US military launched strikes on an Iranian ground control station on Qeshm Island near the Strait of Hormuz in retaliation for Iran's failed missile attacks on Kuwait and Bahrain. This action caused Dow futures to fall slightly while oil prices c...
Clear Junction Group and Agant have partnered to facilitate institutional access to GBPA, a Pound sterling-backed stablecoin designed for practical financial use. This partnership connects fiat GBP payment flows with GBPA issuance and redemption, tar...
